C. Hasenoehrl, M. Storr and R. Schicho. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? Expert Rev Gastroenterol Hepatol. 11(4)329-37. PMID: 28276820
This article concludes that cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines.
A. Fabisiak and J. Fichna. Cannabinoids as gastrointestinal anti-inflammatory drugs. Neurogastroenterol Motil.Mar 29(3)PMID: 28239924
In this mini-review, they focus on the potential of the endocannabinoid system as a target for novel therapies to treat gastrointestinal (GI) inflammation. The authors discuss the organization of the endocannabinoid signaling and present possible pharmacological sites in the endocannabinoid system and refer to recent clinical findings in the field. Finally they point at the potential use of cannabinoids at low, non-psychoactive doses to counteract non-inflammatory pathological events in the GI tract.